Laurion Capital Management LP bought a new position in Dermira Inc (NASDAQ:DERM) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 46,800 shares of the biopharmaceutical company’s stock, valued at approximately $634,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in DERM. Bank of America Corp DE boosted its position in shares of Dermira by 469.9% during the 4th quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock worth $15,619,000 after purchasing an additional 1,791,178 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Dermira by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after purchasing an additional 22,816 shares in the last quarter. Sofinnova Investments Inc. boosted its position in shares of Dermira by 9.5% during the 4th quarter. Sofinnova Investments Inc. now owns 542,224 shares of the biopharmaceutical company’s stock worth $3,899,000 after purchasing an additional 46,931 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new position in shares of Dermira during the 1st quarter worth about $6,779,000. Finally, Geode Capital Management LLC boosted its position in shares of Dermira by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 392,484 shares of the biopharmaceutical company’s stock worth $2,821,000 after purchasing an additional 12,060 shares in the last quarter. Institutional investors own 83.38% of the company’s stock.
Shares of NASDAQ DERM opened at $9.95 on Friday. Dermira Inc has a fifty-two week low of $6.00 and a fifty-two week high of $15.48. The stock has a market capitalization of $534.00 million, a P/E ratio of -1.90 and a beta of 1.32. The company has a current ratio of 7.13, a quick ratio of 6.92 and a debt-to-equity ratio of 4.36.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.39). The business had revenue of $2.45 million during the quarter, compared to the consensus estimate of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. As a group, sell-side analysts expect that Dermira Inc will post -5.2 earnings per share for the current year.
Several equities analysts recently weighed in on the stock. BidaskClub cut shares of Dermira from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Zacks Investment Research cut shares of Dermira from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. HC Wainwright assumed coverage on shares of Dermira in a research report on Thursday, February 14th. They issued a “buy” rating and a $13.00 price target on the stock. Svb Leerink assumed coverage on shares of Dermira in a research report on Friday, February 22nd. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Leerink Swann assumed coverage on shares of Dermira in a research report on Friday, February 22nd. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $18.30.
In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now owns 43,900 shares in the company, valued at approximately $658,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 14.80% of the company’s stock.
WARNING: This report was posted by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thestockobserver.com/2019/05/25/laurion-capital-management-lp-buys-shares-of-46800-dermira-inc-derm.html.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
See Also: What is a Swap?
Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.